Itoprid Fmk (Itopride Hydrochloride)

Itoprid Fmk is a prokinetic agent that acts on gastrointestinal motility disorders.

• Functional dyspepsia: improves post‑prandial discomfort and early satiety by enhancing gastric emptying.
• Gastroesophageal reflux disease: reduces reflux episodes through increased lower oesophageal sphincter tone.
• Irritable bowel syndrome: alleviates abdominal pain and bloating by normalising intestinal transit.

• Itopride hydrochloride enhances gastrointestinal motility by antagonising dopamine D2 receptors in the enteric nervous system and inhibiting acetylcholinesterase, which raises acetylcholine levels. The combined actions increase smooth‑muscle contractility, promote coordinated peristalsis, and improve gastric emptying and lower oesophageal sphincter function.

Adverse reactions may occur with any gastrointestinal prokinetic.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Diarrhoea: increased loose stools.
• Abdominal pain: cramp‑like discomfort.
• Dry mouth: reduced salivation.
• Headache: transient head pain.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Extrapyramidal symptoms: involuntary muscle movements.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Elevated liver enzymes: indication of hepatic stress.
• Neutropenia: reduced white blood cell count.
• Cardiac arrhythmia: irregular heart rhythm.
• Pancreatitis: inflammation of the pancreas.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal function assessment: adjust use in severe impairment.
• Hepatic monitoring: check liver enzymes periodically.
• Elderly caution: start with the lowest effective dose.
• Hypersensitivity review: avoid if known allergy to itopride.
• Concomitant medication review: evaluate for interactions that may affect motility.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Itopride may interact with other medicines that influence dopaminergic or cholinergic pathways.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol): may counteract dopamine antagonism and increase extrapyramidal risk.
• Other prokinetics (e.g., metoclopramide): additive effect on dopamine blockade can heighten neurological side effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents (e.g., atropine): may diminish the pro‑kinetic benefit.
• Antacids containing aluminium or magnesium: can reduce absorption if taken simultaneously.
• Macrolide antibiotics (e.g., erythromycin): potential additive gastrointestinal motility effects.